Skip to main content
WATWaters CorporationHold5.7·$410.70+1.49%

Waters (WAT) Q2 2026 earnings — TrendMatrix coverage

BEAT+1.4% vs estimateEPS $3.05 vs $3.01 estVerdict HoldBuy (Wait)

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
$3.05
Estimate
$3.01
Surprise
+1.4%
Score at report (before → after)
6.16.4/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Report record · Q2 2026

How the report landed

Waters (WAT) beat the $3.01 estimate with diluted EPS of $3.05 — a modest 1.4% upside surprise. TrendMatrix's engine moved from Hold (6.1/10) to Buy (Wait) at 6.4/10 after the report.

Current read · as of 2026-08-23

Where TrendMatrix's rating stands now

TrendMatrix currently rates WAT Hold at 5.7/10.

4 of the last 4 quarters beat the estimate; this quarter's +1.4% surprise compares with a +6.1% four-quarter average. Next scheduled report: 2026-10-30.

What supports the rating

  • Strong earnings beat streak (4/4)
  • Strong growth profile

What argues against it

  • Analyst target reached - limited upside remaining
  • Near 52-week high (2.6% away)
  • Expensive valuation

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$410.70
Price target
$472.30
Stop
$384.66
Upside to target
+15.0%

The stock trades at 102.2× trailing but 24.8× forward earnings — consensus estimates already build in a substantial earnings recovery.

Risk check: RSI 70 — a level conventionally read as overbought; gains at these levels often lean on momentum.

Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.

Healthcare context

WAT at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Diagnostics & Research
Market cap
$40.32B
P/E (fwd)
24.8
P/E (ttm)
102.2
52-week range
$282.77$421.74
Off 52-week high
2.6%
RSI (14)
70
Volume vs avg
0.93×
Score today
5.7/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks WAT Earnings Q2 2026 earnings